AstraZeneca sells beta-blocker commercial rights for $300m

22-05-2017

AstraZeneca sells beta-blocker commercial rights for $300m

Fotonen / iStockphoto.com

Pharmaceutical company Recordati has paid AstraZeneca $300 million for the European commercial rights to beta-blockers.


AstraZeneca, beta-blockers, Recordati, commercial rights

LSIPR